Spectrum Pharmaceutecals Inc (SPPI)

[Tartiaboy]

I don't know if you are aware of the NMIBC bladder cancer drug Vicinium that is in phase III trials for BCG refractive NMIBC. The company SESEN Bio is very small cap.

If SPPI were to acquire SESEN, they would have the beginnings of a NMIBC bladder cancer franchise.

Both drugs are intra-vesiclular administration and I think they may have utility in combination. Bladder cancer is not a small market and SPPI could actually become a leader if they wanted to.

The above would be far more likely to be feasible if Rolontis sales materialize.

We could sell CASI to finance most of SESN acquisiton.